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Background: In most documented literature, metanephric adenoma (MA) is described as a benign tumour.
Nevertheless, the nature of MA remains unclear and the clinical criteria of different MA subtypes are not well
established. In the present study, we investigated the clinicopathological characteristics of MA, especially those
of the uncommon histological subtypes.
Methods: A cohort study was performed on 18 patients with pathologically proven MA in our institute from
January 2004 to June 2014. The patients’ clinicopathological and radiological data were retrospectively analysed
and evaluated with an emphasis on the corresponding subtypes.
Results: The patient population had a female: male ratio of 1:1 and mean age of 50 years (range, 18–66 years). The
mean tumour size was 3.9 cm (range, 1.4–9.0 cm). There were no pathognomonic radiological features that posed a
challenge for a preoperative diagnosis of MA. Fourteen patients underwent radical nephrectomy, and the other
four underwent partial nephrectomy. Three histological subtypes were observed: classic MA (n = 10), malignant MA
(n = 2), and composite MA with coexistence of different malignant components (n = 6). Despite the presence of
atypical histological features and malignant components among the patients, only one patient developed distant
metastasis (median postoperative follow-up, 56 months; range, 30–86 months).
Conclusions: MAs are a heterogeneous group of neoplasms with different biological characteristics. The correct
identification of this entity and its subtypes would facilitate stratification of optimal management protocols and
accurate assessment of the prognosis.
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The term ‘metanephric adenoma’ (MA) was originally
described by Bove in 1979 and is known to be associated
with Wilms’ tumour [1]. To date, fewer than 200 cases
of MA have been reported worldwide in the English-
language literature. In most documented literature, MA
is characterised as a rare benign tumour of the kidney
that accounts for approximately 0.2% of adult renal epi-
thelial neoplasms. It generally occurs in adults and has
an excellent prognosis. Nevertheless, the detailed nature
of MA remains unclear. Several reports have suggested
that a small subset of these tumours has atypical histo-
logical features or even an exponential growth pattern
[2], and the capacity for MA to become malignant has* Correspondence: yuanjieniu@outlook.com
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unless otherwise stated.been reported [3]. However, the clinical criteria of differ-
ent MA subtypes are not well established. In the present
study, we investigated different MA subtypes and aimed
to establish clinical criteria that will facilitate more ac-
curate therapy planning by using pathological findings as
the gold standard. Limited clinical data on MA are avail-
able in the English-language literature. To the best of
our knowledge, this is the largest clinical series to date
focusing on clinical and pathological subtype analysis
of MA.Methods
Study design and patient selection
This retrospective observational cohort study was ap-
proved by the Institutional Review Board of the Second
Hospital of Tianjin Medical University. The study was
approved by all patients and written informed consentsis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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details and images. The medical records of 18 patients
with pathologically proven MA were retrieved from the
archival files and retrospectively analysed in our institute
from January 2004 to June 2014. All pathologic spe-
cimens were acquired after surgery, and none were
diagnosed by biopsy. Preoperative abdominal ultrasound
and computed tomography (CT) examinations were
performed in all cases; magnetic resonance imaging was
performed in only three cases. The patients’ demogra-
phic characteristics, clinical presentation, radiological
characteristics (tumour diameter, location, CT value, and
growth and enhancement patterns), histological findings,
and perioperative and follow-up data were recorded.
Details of the patient’s clinicodemographic characte-
ristics and CT findings are listed in Table 1. Abdominal
biphasic CT scans and three-phase contrast-enhanced
CT scans were performed in all cases. Data on calcifica-
tion, tumour-spreading patterns, lymphadenopathy, and
enhancement patterns (homogeneous, heterogeneous)
were recorded and retrospectively analysed. All patients
were treated surgically; 14 underwent radical neph-
rectomy, and four underwent partial nephrectomy. The
tumour grade was assigned according to the World
Health Organization grading system. All pathological
diagnoses were determined by at least two urological pa-
thologists. In inconclusive cases, the final diagnosis wasTable 1 The clinical, CT and pathological characteristics of MA
NO. Sex/Age (years) Tumor size (cm) Unenhanced
attenuation(
1 F/48 2 37/61
2 F/65 3 30/87
3 M/62 6.2 9/12
4 M/45 4 21/42
5 F/33 2 20/25
6 F/64 4.5 30/46
7 F/53 6.5 36/58
8 M/64 6 45/71
9 F/38 5 46/107
10 M/65 2.7 43/51
11 F/50 9 20/58
12 M/50 4.3 25/53
13 F/38 3.5 25/30
14 M/33 3.5 24/58
15 F/47 4.7 33/76
16 M/43 4 26/64
17 M/51 3 28/34
18 M/18 5.3 32/46
F: female, M: male, RN: radical nephrectomy, NSS: nephron sparing surgery, MA: Metan
PT: Papillary tumor, AC: adenocarcinoma, M: metastasis.determined after consultation with senior pathologists.
No patients received any adjuvant therapeutic modalities.
The median follow-up period was 56 months (range, 30–
86 months). The therapeutic modalities, pathological
findings, and follow-up data are detailed in Table 1. The
types of surgical interventions, complications, postopera-
tive management, and survival results were all retrospec-
tively analysed.
Statistical analysis
The chi-squared test was used for categorical variables.
All reported nonparametric p-values are two-sided, and
statistical significance was set at p < 0.05. Ratios were
compared between the two groups using T tests. All data
were analysed using SPSS, version 17 (SPSS Inc., Chicago,
IL, USA).
Results
Clinical data and surgical treatment
In nine patients, the tumours were incidentally detected
on imaging studies performed for unrelated clinical pre-
sentations. Gross haematuria was found in five patients,
and loin pain was present in four patients. For small
tumours (<4 cm), the choice of surgical approach de-
pended on the patient’s compliance and the attending
urologist’s individual preference. In complicated circum-
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ephric adenomas, CCC:chromophobe cell carcinoma, OC: Oncocytic carcinoma,
Figure 2 CT showing a heterogeneous or centrally located
low-attenuation mass.
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partial nephrectomy is very difficult. Surgical parameters
including tumour stage, tumour size, operating time,
warm ischaemia time, and complications were docu-
mented. In the partial nephrectomy group, the mean pre-
operative tumour size was 2.5 cm (range, 1.4–3.5 cm), and
the clinical stage was T1a. All patients in the partial neph-
rectomy group underwent pedicle clamping, and the
mean (± standard deviation) warm ischaemia time was
26 ± 6 min. All surgical margins were negative. In the
radical nephrectomy group, the mean preoperative
tumour size was 5.2 cm (range, 3.5–9.0 cm), and the cli-
nical stages were T1a (n = 13) and T1b (n = 1). One pa-
tient underwent resection of an enlarged lymph node with
a pathologically proven inflammatory reaction. All pa-
tients tolerated the surgery well and had an unremarkable
postoperative recovery.
Radiological findings
Ten tumours were found on the right side and eight were
found on the left side. Seven tumours were found in the
upper pole of the kidney, five in the middle pole, and six
in the lower pole. The most common imaging characte-
ristic on unenhanced abdominal CT was the presence of
homogeneous, well-defined solid renal masses (n = 15,
83.3%) (Figure 1); the least common was the presence of
heterogeneous or centrally located low-attenuation masses
(n = 3, 16.7%) (Figure 2). Contrast-enhanced CT revealed
heterogeneity and varying degrees of enhancement in 16
(88.9%) tumours (Figure 3), while 2 (11.2%) tumours did
not exhibit increased attenuation. Scattered calcification
and an enlarged lymph node were found in only one pa-
tient (5.6%).
Pathological findings
Macroscopically, the MAs ranged in size from 1.4 to
9.0 cm (mean, 4.5 cm). The cut surface was a homogenousFigure 1 CT showing the presence of homogeneity and well-defined
solid renal masses.tan or yellowish-white colour, and the tumour was an en-
capsulated, generally well-circumscribed mass (Figure 4).
Microscopically, the MAs comprised variable proportions
of proliferating cells forming small glomeruloid bodies
(Figure 5). The tumour cells had uniformly small and indis-
tinct nucleoli and scanty cytoplasm (Figure 6). Immunohis-
tochemical staining showed that most tumour cells were
positive for WT-1 (Figure 7), CD57 (Figure 8), MIB-1,
Vimentin, and EMA, while CK7 staining showed weak
focal positivity. In two cases, the tumour cells exhibited
epithelial elements, lacked the typical architecture of tu-
bules and glomeruloid bodies, and showed atypia and mi-
totic activity (Figure 9). The proliferation index of theFigure 3 Contrast-enhanced CT image revealed heterogeneous and
varying degrees of enhancement.
Figure 4 Macroscopically, MA revealed a homogenous tan or
yellowish-white colour cut surface and the encapsulated tumour
generally formed well-circumscribed mass.
Figure 6 Tumours cells had uniformly small and indistinct nucleoli,
and scanty cytoplasm.
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lowing composite tumours with foci of malignant tumour
cells were found in six patients: papillary tumour (n = 3),
oncocytic carcinoma (n = 1), adenocarcinoma (n = 1), and
chromophobe cell carcinoma (n = 1). The 18 cases were
divided into three subtypes according to the pathological
findings: classic MA (n = 10), malignant MA (n = 2), and
composite MA with coexistence of different malignant
components (n = 6). Pathological examination revealedFigure 5 Microscopically,the tumour was composed of variable
proportions of cells proliferated with formation of small
glomeruloid bodies.that six (33.3%) tumours had other carcinoma components
concomitantly and that two (11.1%) were malignant MA,
with a surprisingly high proportion of malignant case. All
of these pathological findings indicated the presence of
MA subtypes and provided useful information. When
stratified by malignant component groups, no significant
difference in prognosis was found (p > 0.05).
Follow-up
All patients were followed up with physical examinations,
laboratory tests, chest X-rays, and renal ultrasound or ab-
dominal CT every 3–6 months and then annually. Clinical
outcomes were estimated from the date of surgery to the
date of death or last follow-up. The median postoperative
follow-up period was 56 months (range, 30–86 months),
and no local recurrence or metastatic lesions were found
with the exception of one patient who developed distant
metastasis pathologically diagnosed as malignant MA.Figure 7 Immunohistochemical staining revealed most tumor cells
were positive expression of WT-1 (original magnification, ×200).
Figure 8 Immunohistochemical staining of tumor cells were positive
for CD57 (original magnification, ×200).
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MA was well recognised as a distinct entity in 1988 and
was subsequently considered to be a separate entity [3].
The concept of MA has recently been broadened to in-
clude MAs, adenofibromas and stromal tumours. There
is a female preponderance and a peak age of occurrence
in the fifth or sixth decade of life. MA constitutes ap-
proximately 0.2% of all adult renal epithelial neoplasms.
The incidence of MA in our institution accounts for <1%
of all renal tumours, similar to previous reports. Ap-
proximately 100 cases of MA have been reported in the
English-language literature to date [1]. However, most re-
ports focused mainly on pathology; few reports on the
clinical or radiological features are available.
Histogenetically, MA contains renal epithelial or stro-
mal cells. It is postulated to be a benign counterpart ofFigure 9 Tumour cells were composed of epithelial elements and
lack of typical architecture of tubules and glomeruloid bodies
(original magnification, ×100), atypia and mitotic activity were
present (original magnification, ×200).Wilms’ tumour and may be derived from remnants of
metanephric blastemal or embryonic renal tissue. MA is
considered to represent the most hyperdifferentiated end
of the nephroblastoma spectrum and might sometimes
coexist with Wilms’ tumour [4]. The genetic profile and
chromosomal abnormalities of MA are distinct from those
of papillary renal cell carcinoma and Wilms’ tumour. The
simultaneous presence of BRAF gene mutation and 2p de-
letion plays a great role in the pathogenesis of MA [5].
Microscopically, the tumour cells have uniformly small
and indistinct nucleoli with scanty cytoplasm. Variable
proportions of cells proliferate with the formation of
small glomeruloid bodies. Immunohistochemical staining
shows that most tumour cells are positive for MIB-1,
vimentin, EMA, WT-1, and CD57; in contrast, CK7 stai-
ning exhibits weak focal positivity. In rare cases, the
tumour cells have epithelial elements, lack the typical
architecture of tubules and glomeruloid bodies, and show
atypia and mitotic activity. Atypical MA needs to be diffe-
rentiated from Wilms’ tumour, nephrogenic rests, and pap-
illary renal cell carcinoma [6]. MA has morphological
similarities to solid papillary renal cell neoplasms; both
exhibit significant similarities such as well-circumscribed
tumours comprising small tightly packed cells arranged in
solid sheets or ill-defined tubules. Some of the morpho-
logical features overlap; thus, the differential diagnosis is
crucial. MA must also be distinguished from metastatic
cancers, particularly those of the thyroid gland and lung.
Despite the overlapping features, careful morphological
evaluation, especially immunohistochemical staining with
CD57, WT1, and CK7, may be useful for differentiation
and accurate diagnosis. Meanwhile, genetic analysis may
facilitate discrimination in difficult cases. The presence of
cytological atypia, mitoses, and anaplastic foci favour the
diagnosis of malignant MA, especially distant metastasis.
Malignant MA tumours such as metanephric adenocar-
cinoma, mixed MA, and papillary carcinoma have also
been reported [7].
Surprisingly, tumours with typical histological charac-
teristics of MA can present with metastatic disease [2]. Al-
though the natural history of these composite tumours is
unknown, they theoretically exhibit aggressive behaviour
and the potential for metastasis. In the present study, MA
with other concomitant tumour types was determined to
be composite MA. This was based on the existing lite-
rature stating that a tumour mainly comprising MA that
exhibits sporadic concurrent tumours should be classified
as a subtype of MA. Composite MA with a co-existing
malignant component such as papillary renal cell carcin-
oma also has metastatic potential [8,9]. The features of
these composite tumours are emphasised to promote a
better and broader understanding of this uncommon
tumour. Notably, oncocytic carcinoma, renal adenocar-
cinoma, and chromophobe cell carcinoma mixed with
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gation. Meanwhile, the cells of two tumours had atypical
epithelial elements and mitotic activities, lacked the
typical architecture of tubules, and glomeruloid bodies,
and were pathologically diagnosed as malignant MA; one
tumour was found to be a lung metastasis 46 months
postoperatively. The pathological criteria of malignant
MA are not well established, and rare metastatic MA has
been reported. In contrast to typical MA, malignant MA
comprises hypercellular uniform cells in a solid-acini pat-
tern; the cells are variable in size, the nucleoli are promi-
nent, and some cells show increased numbers of mitoses
with small uniform nuclei. The diagnosis of malignant
MA requires the incorporation of clinical information,
histopathological features, and related immunohistoche-
mical staining markers.
Clinically, MA occurs predominantly in adult women
and rarely in children,the reported age ranged from
15 months to 83 years [10]. Most patients with MA are
asymptomatic or present with nonspecific clinical mani-
festations such as haematuria, a palpable mass, flank
pain, or chyluria [11]. Polycythaemia, which may be as-
sociated with para-neoplastic syndrome, is frequently re-
ported among patients with MA. Most patients in the
present series were asymptomatic, and no special symp-
toms were noted. The regular performance of physical
examinations has led to a rise in the incidental detection
of asymptomatic renal masses. Additionally, MA may be
multifocal or bilateral [12,13]. Laboratory tests would be
less useful in this setting because no special tumour
markers are noted. Urinalysis and renal and hepatic
function tests were essentially within normal limits in
our series.
Various imaging modalities may be used to characterise
MAs. With respect to echogenicity, MA is a hypovascular
tumour and has most often been described as a hypere-
choic mass [14]. However, the tumours in the present
study were hypoechoic, isoechoic, and hyperechoic in
nine, four, and five patients, respectively. Abdominal
three-phase contrast-enhanced CT was performed in all
18 patients, and no obvious correlations between morpho-
logic features and characteristic CT imaging features were
found. No radiological findings were of substantial help in
differentiating MA from malignant renal tumours, espe-
cially for small masses. In our series, data on the tumour-
spreading patterns, lymphadenopathy, and enhancement
patterns were recorded and retrospectively analysed. An
enlarged lymph node was noted in one patient; the node
was pathologically proven to have an inflammatory re-
action, similar to a pseudometastatic lesion. The most
common CT imaging characteristic was the presence of
homogeneous and well-defined solid renal masses (n = 15,
83.3%), and the least common was the presence of hete-
rogeneous or centrally located low-attenuation masses(n = 3, 16.7%). Contrast-enhanced CT revealed hypoatte-
nuating heterogeneous masses with varying degrees of
contrast enhancement in 16 (88.9%) patients, while 2
(11.2%) did not show increased attenuation. On unen-
hanced CT, one tumour (5.6%) showed scattered calcifica-
tion with higher attenuation than the renal parenchyma.
MA appears to be more commonly calcified than other
neoplasm [15], which is speculated to be related to the
presence of psammomatous calcification or a high nuclear-
to-cytoplasmic ratio. Less frequently reported is hypoatte-
nuation or predominantly cystic lesions consistent with
necrosis [16]. The hypovascularity of MA seems to reflect
the histological findings of mainly acinar and tubular pat-
terns with few vessels. The magnetic resonance imaging
features of MA are unspecific; limited cases showed
hypointense or isointense lesions on both T1- and T2-
weighted magnetic resonance images [17].
Given the rarity of this tumour and lack of pathogno-
monic clinical and radiographic criteria, pathologic exa-
mination is necessary to establish a definitive diagnosis.
Because of the undetermined radiological characteristics
of MA, several reports recommend percutaneous fine-
needle aspiration to confirm the diagnosis preoperatively
[18]. However, differentiation of MA from Wilms’ tumour
based on fine-needle aspiration biopsy may be difficult
[19]. MA may be mixed with other neoplasms that may
not be detected by intraoperative biopsy; thus, intraopera-
tive frozen section is not recommended.
From a diagnostic and therapeutic viewpoint, most
renal masses should be regarded as malignant and man-
aged surgically; the exception is small renal masses with
clinically benign behaviour. Accurate preoperative diag-
nosis could facilitate optimal management. More wide-
spread recognition of this rare tumour and its subtypes
is of great importance for appropriate management of
this disease. Our initial classification of three subtypes of
MA may contribute to the establishment of guidelines
for the management of MA and help in selecting an ap-
propriate surgical method.
Awareness of these subtypes may avoid diagnostic con-
fusion, especially when percutaneous biopsy is indeter-
minate. When choosing a treatment modality, it might be
possible to propose conservative treatment or active sur-
veillance, especially in patients with contraindications to
surgery [20]. It should be emphasised that these tumours
may not be entirely benign and that their biologic be-
haviour is uncertain, particularly malignant tumours and
those with malignant components. Thus, careful active
surveillance may be needed even for MAs of <4 cm. Con-
tinued growth or metastatic potential may be lethal; in
our opinion, therefore, MA should be routinely resected.
Although nephron-sparing surgery is currently the refe-
rence standard treatment for clinically localised T1a renal
tumours, subjective clinical factors such as surgeon biases
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more likely influence the decision-making process regar-
ding the most appropriate treatment method. Small renal
tumours, especially exophytic and peripheral tumours, are
ideal candidates for nephron-sparing surgery, either open
or laparoscopic partial nephrectomy [21]. Several effica-
cious therapeutic procedures, such as cryoablation or ra-
diofrequency ablation, are alternative treatment options
[22]. In our series, 14 patients underwent radical nephrec-
tomy and only four underwent partial nephrectomy. Most
of our patients underwent nephrectomy mainly because of
the difficult preoperative differentiation of their lesions
from malignant renal tumours. Because imaging is unable
to exclude renal cell carcinoma, centrally located or ana-
tomically complex masses should be treated by radical
nephrectomy [23].
Patients with MA treated with partial or total nephrec-
tomy have an excellent prognosis. Only one patient in the
present series developed distant metastasis 46 months
after surgery. Long-term active surveillance is necessary
because of the uncertainty of the biological behaviour and
potentially composite malignant components of MA. Fur-
ther studies on various subtypes are needed to identify the
possibility or occurrence of metastasis. Metastatic MA
containing foci of papillary carcinoma to local lymph
nodes were reported in one study; surprisingly, however,
the metastatic lesion was an MA, not a papillary carci-
noma [7]. Therefore, aggressive intervention is needed for
composite MA with a coexisting malignant component.
There were several limitations in the present study.
First, the retrospective design and involvement of a single
centre might have introduced patient selection bias as well
as treatment bias with respect to surgeon preference. Ad-
ditionally, the time interval of 10 years may have changes
in surgical techniques in our institute. Second, there was
lack of further molecular analysis of each subtype to
elucidate its histogenesis. Third, certain limitations were
unavoidable considering the relatively small number of
patients and the scarcity of different tumour subtype
variants. Moreover, it was not possible to determine the
percentage of morphological differentiation in the whole
group of specimens. Because only two malignant cases
were included in this study, statistical analysis and deter-
mination of significant differences were limited.
Conclusions
We demonstrated multiple variations in MA subtypes,
suggesting that their classification spectrum might be
wider than originally described. These interesting fin-
dings urge timely surgical treatment in all patients with
MA. The concept of the disease risk associated with ma-
lignant potential has been developed to aid clinicians
when deciding on treatment strategies; therefore, regular
follow-up is recommended.Competing interests
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